Trump’s Marijuana Move STUNS Conservatives

Detail,Shot,Of,A,Young,Man,Smoking,In,Front,Of

A potential reclassification of marijuana by President Trump could mark a significant shift in drug policy, sparking debate among conservatives concerned about donor influence and regulatory implications.

Story Highlights

Trump considers reclassifying marijuana from Schedule I to Schedule III, influenced by donor discussions.
White House reviewing the policy amid concerns of donor influence and potential backlash.
Cannabis industry executives advocate for rescheduling due to economic and regulatory benefits.
Rescheduling could ease federal-state conflicts but raises concerns about moral implications.

Trump’s Consideration of Marijuana Reclassification

President Trump is evaluating the reclassification of marijuana from Schedule I to Schedule III, according to accounts from attendees at a recent high-profile fundraiser reported by Fox Business and Daily Beast. The Controlled Substances Act currently places marijuana alongside drugs like heroin, restricting medical research. The move to Schedule III could recognize its medical use, aligning federal policy with state legalizations. Outlets such as Daily Beast have reported that cannabis industry leaders, including executives from companies like Trulieve, have made substantial contributions to Trump-aligned groups, a dynamic some analysts see as highlighting the intersection of policy and political fundraising.

The White House has initiated a review process, gathering agency positions to assess the policy’s legal implications. The administration’s actions appear to continue the rescheduling process started under Biden, reflecting growing bipartisan support for reform. According to Marijuana Moment, certain White House advisers have expressed concern that such a move may run counter to long-standing conservative positions on drug policy and federal oversight.

Historical Context and Policy Implications

Marijuana’s current classification as a Schedule I drug has long been contested, especially as various states have legalized its use for medical and recreational purposes. The Biden administration began a process to reschedule marijuana, which Trump’s administration is now reconsidering. This development follows the 2018 Farm Bill’s removal of hemp from Schedule I, a change that altered how the federal government classified and regulated hemp production. Rescheduling could ease tax burdens and enable more comprehensive research, but it wouldn’t fully address federal-state legal conflicts.

If reclassified, cannabis companies could benefit from tax relief and expanded research opportunities, yet banking and interstate commerce barriers would persist. The potential reclassification aligns with public opinion favoring reform, yet it risks alienating prohibitionist constituencies. As the administration weighs the decision, it must consider both the economic opportunities and social implications of such a policy shift.

Stakeholders and Decision Dynamics

Key stakeholders in this decision include President Trump, who can direct the DOJ and DEA to initiate rulemaking, and the White House Chief of Staff, who has compiled agency inputs. Industry leaders, particularly those from companies like Trulieve, play a significant role in advocating for rescheduling. Their financial support and lobbying efforts have been cited by Daily Beast and Fox Business as examples of how donor engagement can coincide with policy discussions. Federal agencies, tasked with providing legal and scientific evaluations, are central to the decision-making process.

If @POTUS does this, it will be a boon for THC based treatment for veterans.

Trump considers reclassifying marijuana as less dangerous drug: report | Fox Business https://t.co/BKy0TJynqG

— TheDocDyrtybird (@dyrtybird) August 11, 2025

As the Trump administration navigates this complex issue, it must balance political interests, donor expectations, and public health considerations. The potential rescheduling could pave the way for broader reforms, but sources note that it will require deliberation to address the concerns of stakeholders, including those who prioritize maintaining alignment with conservative policy positions.